Rezolute, Inc.
Rezolute, Inc. (RZLT): 7 pipeline candidates · 2 upcoming catalysts · ~20 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
19.9 months
D/E 0.07 · 8% dilution
Lead: Phase 3
7 candidates
2 upcoming, next in ~440d
1 buy · 0 sells (180d)
A transparent, data-derived signal for Rezolute, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$428.0M
Cash
$11.2M
Quarterly Burn
$17.4M
Runway
19.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| ersodetug | Phase 3 |
| experimental | Phase 2 |
| rz358 sequential group cohort 1 | Phase 2 |
| rz358 sequential group cohort 2 | Phase 2 |
| rz358 sequential group cohort 3 | Phase 2 |
| rz358 sequential group cohort 4 | Phase 2 |
| rz402 | Phase 2 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
125
Total value held
$251.9M
| Holder | Shares | Value |
|---|---|---|
| federated hermes, inc. | 12,990,659 | $39.6M |
| ra capital management, l.p. | 9,180,000 | $28.0M |
| vanguard capital management llc | 7,044,160 | $21.5M |
| blackrock, inc. | 6,313,503 | $19.3M |
| balyasny asset management l.p. | 5,048,421 | $15.4M |
| jennison associates llc | 3,438,881 | $10.5M |
| vanguard portfolio management llc | 2,981,765 | $9.1M |
| bank of america corp /de/ | 2,970,549 | $9.1M |
| morgan stanley | 2,747,671 | $8.4M |
| integral health asset management, llc | 2,000,000 | $6.1M |
Showing top 10 of 125 institutional holders of Rezolute, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Rezolute, Inc.'s pipeline?
Rezolute, Inc. (RZLT) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Rezolute, Inc.'s lead drug candidate?
Rezolute, Inc.'s most advanced tracked candidate is ersodetug (Phase 3) for Tumor Hyperinsulinism (Tumor HI).
What is Rezolute, Inc.'s next catalyst?
Rezolute, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Co" — expected September 1, 2027.
What is Rezolute, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Rezolute, Inc. has approximately 19.9 months of cash runway.
What is Rezolute, Inc.'s market capitalization?
Rezolute, Inc.'s market capitalization is approximately $428.0M.
Get the full picture on Rezolute, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.